Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

Marie Skłodowska-Curie Action · Running

CRISPRGlue Customized Surface-Engineered “Nanoglue”: Unlocking Ultrasound-Triggered targeted delivery of CRISPR/Cas complex for Glioblastoma

Coordinator
Universidad Del Pais Vasco/ Euskal Herriko Unibertsitatea, Spain
Runs
1 February 2026 to 31 January 2028
Status
Running
EU funding
€210k
Total cost
—
Partners
3 organisations in 2 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101210766

What the project is doing

In the project's own words, from its summary on CORDIS.

Glioblastoma multiforme (GBM), constituting 50.1% of CNS tumors, is the most frequent malignant brain cancer with a median survival of 14.6 months, highlighting the urgent need for more effective treatment strategies. The rise of effective gene therapies especially CRISPR/Cas (“clustered regularly interspaced short palindromic repeats/associated protein 9”) based gene editing technology has sparked optimism for treating GBM.

Given the ongoing challenges with CRISPR-Cas gene therapy, such as effective delivery across the blood-brain barrier (BBB), off-target effects, and immune responses associated with Cas9, this research proposal (CRISPRGlue) aims to develop ""nanoglues,"" a novel class of engineered nanogels for targeted delivery of CRISPR tools followed by ultrasound triggered release to address GBM treatment challenges at a European level.

The gene editing efficacy of the CRISPR/Cas tools delivered by “nanoglues” will be preliminary investigated as a “proof of concept” by knock-down approach with GFP expressed U87MG cell line followed by targeting EGFR genes which are highly overexpressed in GBM sites. The project unites a dynamic researcher, Dr. Soumen Ghosh, with expertise in synthetic organic chemistry and protein science, alongside POLYMAT, an innovative institute focused on biomedical solutions utilizing nanogels for the controlled release of the CRISPR/Cas9 complex.

Prof. Marcelo Calderón, the host supervisor, is a globally recognized researcher leading the “Responsive Polymer Therapeutics Group (RPTG),” a top team specializing in drug delivery using nanogels (NGs). The multidisciplinary expertise required for CRISPRGlue will be complemented by the Smart Bio-Interfaces group led by Prof. Gianni Ciofani. CRISPRGlue will advance the researcher’s career in both academic and non-academic fields by developing non-viral gene delivery systems to facilitate curative gene editing, empowering him to drive the translation of laboratory findings to pre-clinical trials.""

Topics

Who is involved

OrganisationCityCountryRole
Universidad Del Pais Vasco/ Euskal Herriko UnibertsitateaLeioaSpainCoordinator
Basque Center for Macromolecular Design and Engineering Polymat FundazioaDonostia San SebastianSpainAssociatedpartner
Fondazione Istituto Italiano Di TecnologiaGenovaItalyAssociatedpartner

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI